Diabetes
Conditions
Interventions
Intervention Group:3 L PEG fractional lavage + lubiprostone
Control group:3 L PEG for bowel wash
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Participants must meet all of the following 4 conditions: 1.Aged between 18 and 75 years, regardless of gender; 2.Diagnosed with type 2 diabetes and currently receiving GLP-1 receptor agonist treatment for more than 8 weeks (no restrictions on the type of GLP-1 receptor agonist); 3.Plan to undergo colonoscopy (including screening, diagnostic, surveillance colonoscopy); 4.Voluntarily agree to participate in the study and sign an informed consent form.
Exclusion criteria
Exclusion criteria: Exclusion Criteria: Any of the following conditions: 1.Known or suspected allergy to bowel preparation drugs, such as PEG or Lubiprostone; 2.Suspected or confirmed bowel obstruction, bowel perforation, or foreign body in the bowel; 3.Toxic megacolon; 4.Uncontrolled hypertension (systolic blood pressure >170 mmHg, diastolic blood pressure >100 mmHg); 5.Shock or hemodynamic instability; 6.Severe electrolyte disturbances; 7.Coagulation disorders (prolonged prothrombin time (PT) greater than 3 seconds above the normal upper limit); 8.Congestive heart failure (New York Heart Association functional class III or IV); 9.Respiratory failure; 10.Decompensated cirrhosis; 11.Severe renal impairment (estimated glomerular filtration rate (eGFR) <30 ml/min); 12.Thoracoabdominal aortic aneurysm; 13.History of stroke, acute myocardial infarction, or unstable angina within the past 6 months; 14.History of colon surgery; 15.Pregnant or breastfeeding women; 16.Use of prokinetic drugs within the past week; 17.If the patient is using a long-acting GLP-1 receptor agonist, the drug discontinuation period exceeds 3 half-lives; 18.Severe constipation (as assessed by the Chronic Constipation Severity Score (CSS), exclusion if the score is greater than 15); 19.Participation in other drug/device studies or in the follow-up period of another drug/device study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bowel Preparation Adequacy Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Boston Bowel Preparation Scale Score;Cecal Intubation Rate;Cecal Intubation Time;Polyp Detection Rate;Adenoma Detection Rate;Tolerability of bowel preparation;The willingness of subjects to undergo similar bowel preparation in the future; | — |
Countries
China
Contacts
Public ContactKai Deng
West China Hospital, Sichuan University
Outcome results
None listed